Sala de Situação aberta com dados administrativos para gestão de Protocolos Clínicos e Diretrizes Terapêuticas de tecnologias providas pelo SUS

Ferré, Felipe; Oliveira, Gustavo de L. T.; Queiroz, Mariana De; Gonçalves, Flávio de Oliveira

doi:10.5753/sbcas.2020.11530

Cited by 5 publications

(6 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ferré et al 29 bring an important approach to SSH, which is the function of supporting strategic planning, as well as knowledge management. These are only possible because the SSS generates evidence from historical data, according to the interest in generating this data.…”

Section: Discussionmentioning

confidence: 99%

Development and assessment of situation room in a stroke unit using low-code technology

Santana,

Barbosa

2024

Health of Tomorrow: Innovations and Academic Research

View full text Add to dashboard Cite

The Health Situation Room (SSS) is a virtual or physical environment that provides a set of data grouped by spreadsheets or systems, to obtain information and monitor indicators, as in the case of Cerebrovascular Accident (CVA). In order to incorporate a new context of SSS application in a hospital environment and to use the concept and application of low-code or no-code technologies in public health, this study aimed to develop and evaluate SSS in a Stroke Unit of a University Hospital. The research was developed in the following stages: requirements gathering, modeling of use cases, definition of the low-code platform, definition of profiles and the SSS panel and production of the final prototype. As a result, the following were made available: the standardized data entry form; connection with the database of the UH hospital information system for patient searches; and, SSS panel for evaluation. This work proved to be very successful in its implementation with the use of the low-code tool, due to the robustness in the number of tools provided by the platform. The solution was also very well evaluated by the care team that participated in the study, demonstrating its potential for use in the health area.

show abstract

Section: Discussionmentioning

confidence: 99%

Development and assessment of situation room in a stroke unit using low-code technology

Santana,

Barbosa

2024

Health of Tomorrow: Innovations and Academic Research

View full text Add to dashboard Cite

show abstract

“…Cost-effectiveness analysis through a Decision Tree. Guideline for the Analysis of Budgetary Impact of the Ministry of Health (MS) 13 . The time horizon adopted was five years, according to MS Guidelines.…”

Section: Model Chosenmentioning

confidence: 99%

Cost-effectiveness analysis of cinacalcet vs. paricalcitol in the treatment of hyperparathyroidism secondary to chronic kidney disease

et al. 2023

View full text Add to dashboard Cite

Introduction For the reduction of PTH levels, two classes of drugs are available in the Brazilian market: non-selective and selective vitamin D receptor activators and calcimimetics. Among the mentioned drugs, the SUS provides oral calcitriol, paricalcitol and cinacalcet. Objectives: Develop cost-effectiveness (CE) and budgetary impact (BI) analysis of cinacalcet versus paricalcitol for patients on dialysis with SHPT, from the perspective of SUS. Methodology: A decision tree model was constructed for CE analysis, which considered the outcome of avoided parathyroidectomy and a time horizon of 1 year. As for the BI analysis, two scenarios were considered, one of which was measured demand and other epidemiological, based on data from the Brazilian Society of Nephrology (BSN). Results: The CE analysis showed that the use of cinacalcet results in one-off savings of R$1,394.64 per year and an incremental effectiveness of 0.08, in relation to avoided parathyroidectomy. The incremental CE ratio (ICER) was - R$ 17,653.67 per avoided parathyroidectomy for cinacalcet, as it was more effective and cheaper compared to paricalcitol. As for the BI analysis, it was estimated that the incremental BI with the expansion of the use of cinacalcet in the SUS will be between - R$ 1,640,864.62 and R$ 166,368.50 in the first year, considering the main and the epidemiological scenarios. At the end of 5 years after the expansion of use, an BI was estimated between - R$ 10,740,743.86 and - R$ 1,191,339.37; considering the same scenarios. Conclusion: Cinacalcet was dominant to avoid parathyroidectomies, being cost-effective.

show abstract

“…The time horizon used was 5 years, according to MS Guidelines. populAtIon Three scenarios were considered: the main one of measured demand, based on data from the Department of Pharmaceutical Assistance and Strategic Inputs of the Ministry of Health (DAF); the alternative of measured demand, based on data from the Open Room of Health Intelligence (SABEIS) 11 ; and the epidemiological alternative, based on data from the Brazilian Society of Nephrology (SBN).…”

Section: Budget Impact Analysismentioning

confidence: 99%

Cost-effectiveness analysis of intravenous paricalcitol vs. oral calcitriol in the treatment of hyperparathyroidism secondary to chronic kidney disease

et al. 2023

View full text Add to dashboard Cite

Introduction: Hyperparathyroidism (SHPT) secondary to chronic kidney disease (CKD) is characterized by high levels of parathyroid hormone (PTH), hyperplasia of the parathyroid glands and cardiovascular disease. Selective and non-selective and selective vitamin D-receptor activators, calcimimetics, are available in the Brazilian market to reduce PTH levels. Objectives: To develop a cost-effectiveness (C/E) and budgetary impact (BI) analysis of intravenous paricalcitol vs. oral calcitriol for patients on dialysis with SHPT, from the perspective of the Brazilian Public Health Care System (SUS). Methodology: We built a decision-tree model to analyze C/E, which considered the outcome of avoided death and a time horizon of 1 year. As for the BI analysis, two scenarios were considered, one of demand and one of epidemiological approach, based on data from the Brazilian Society of Nephrology. Results: The analysis showed that the C/E ratio was R$ 1,213.68 per year, and an incremental effectiveness of 0.032, referring to avoided death. The incremental C/E ratio was R$37,927.50 per death averted by paricalcitol. It was estimated that the incremental BI with the expansion of paricalcitol use will be between R$1,600,202.28 and R$4,128,565.65 in the first year, considering the main and epidemiological scenarios. At the end of 5 years after the expansion of its use, an incremental BI was estimated between R$ 48,596,855.50 and R$ 62,90,555.73. Conclusion: Intravenous paricalcitol has superior efficacy and similar safety to oral calcitriol, reducing the overall mortality of dialysis patients, although it implies a higher cost.

show abstract

Sala de Situação aberta com dados administrativos para gestão de Protocolos Clínicos e Diretrizes Terapêuticas de tecnologias providas pelo SUS

Cited by 5 publications

References 7 publications

Development and assessment of situation room in a stroke unit using low-code technology

Development and assessment of situation room in a stroke unit using low-code technology

Cost-effectiveness analysis of cinacalcet vs. paricalcitol in the treatment of hyperparathyroidism secondary to chronic kidney disease

Cost-effectiveness analysis of intravenous paricalcitol vs. oral calcitriol in the treatment of hyperparathyroidism secondary to chronic kidney disease

Contact Info

Product

Resources

About